AbbVie
Edit

AbbVie

http://www.abbvie.com/
Last activity: 11.09.2026
Active
Categories: CareDrugHealthTechInformationMedTechNewsOwnProductScienceService
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.
Likes
13.88K
Followers
778.54K
Website visits
840.8K /mo.
Mentions
357
Location: United States, Illinois, City of Chicago
Employees: 10001+
Founded date: 2013

Investors 4

Mentions in press and media 357

DateTitleDescription
11.09.2026Great Place To Work™ Greater China Celebrates the Best Workplaces™ in Taiwan 2026Inspiration — the strategic pillar of high‑trust leadership that shapes culture, reinforces trust, and aligns collective purpose. TAIPEI, Sept. 11, 2026 /PRNewswire/ -- On Sept. 10, Great Place To Work™ proudly hosted the Best Workplaces™ i...
01.09.2026Senticell Raises $7M in Seed FundingSenticell, a Philadelphia, PA-based biotechnology company developing a new class of liquid biopsy built on red blood cell (RBC)-bound nucleic acids, raised $7M in Seed funding. Backers included The Venture City, Capital Factory, Scalpel Ven...
19.08.2026Pharmaceutical Contract Manufacturing Market to Reach USD 311.95 Billion by 2030The global Pharmaceutical Contract Manufacturing Market is projected to grow from USD 209.90 billion in 2025 to USD 311.95 billion by 2030, registering a CAGR of 8.2% during the forecast period. Growth is being driven by the increasing outs...
14.08.2026Pharmaceuticals Market Trends: Innovation, Rising Healthcare Demand, and Advanced Therapies Driving GrowthThe pharmaceuticals market is witnessing strong growth as rising healthcare needs, increasing disease prevalence, expanding access to medicines, and continuous innovation in drug development drive global demand. Pharmaceutical products play...
30.07.2026Continuity Biosciences Appoints Vicky Papoutsis to Board of DirectorsBusiness development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vic...
29.07.2026AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian CancerELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peri...
24.07.2026Pharmaceutical Frontier: Psychedelics Rise, GLP-1s Diversify, Global Innovation ThrivesThe pharmaceutical industry undergoes rapid transformation. Big Pharma embraces psychedelic drugs, acquiring key innovators to treat diverse mental health conditions. This signals a new era for depression, PTSD, and anxiety therapies. Concu...
23.07.2026Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNHBEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the Nati...
20.07.2026What to know about testosterone replacement therapy as the U.S. military plans to test troopsTestosterone replacement therapy is back in the spotlight after the U.S. military said it will begin testing service members’ testosterone levels and make replacement therapy available to those who qualify. The therapy is a synthetic form o...
19.07.2026The market for psychedelic drugs to treat mental health conditions gets a big buy signalTo learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embr...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In